TCON logo

TRACON Pharmaceuticals (TCON) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 January 2015

Indexes:

Not included

Description:

TCON (TRACON Pharmaceuticals) is a biopharmaceutical company focused on developing targeted therapies for cancer and other diseases. They aim to improve patient outcomes through innovative treatments, leveraging advanced technology and research to address unmet medical needs in oncology.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Nov 22, 2024

Recent annual earnings:

Mar 05, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Apr 10, 2024

Analyst ratings

Recent major analysts updates

01 July '24 HC Wainwright & Co.
Neutral
03 Apr '24 HC Wainwright & Co.
Buy
06 Mar '24 HC Wainwright & Co.
Buy
20 Nov '23 HC Wainwright & Co.
Buy
21 Aug '23 JonesTrading
Hold
15 Aug '23 Baird
Outperform
11 May '23 Maxim Group
Buy
11 May '23 Baird
Outperform
09 Mar '23 HC Wainwright & Co.
Buy
23 Feb '22 Baird
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

TRACON Pharmaceuticals Announces it Will Wind Down Operations
TRACON Pharmaceuticals Announces it Will Wind Down Operations
TRACON Pharmaceuticals Announces it Will Wind Down Operations
TCON
globenewswire.com30 July 2024

SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.

TRACON Pharmaceuticals, Inc. (TCON) Q1 2024 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (TCON) Q1 2024 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (TCON) Q1 2024 Earnings Call Transcript
TCON
Seeking Alpha14 May 2024

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2024 Earnings Conference Call is scheduled for May 14, 2024 at 4:30 PM ET. Presenting on the call will be Charles Theuer, President & CEO, and Scott Brown, CFO. Joining the call will be Matthew Venezia from Alliance Global Partners. Thank you for joining us today. Please note that all participants are currently in listen-only mode.

TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
TCON
GlobeNewsWire28 February 2024

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2023 financial and operating results after the close of U.S. financial markets on Tuesday, March 5, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

Why Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today?
Why Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today?
Why Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today?
TCON
InvestorPlace21 November 2023

Tracon Pharmaceuticals (NASDAQ: TCON ) stock is rocketing higher on Tuesday as investors react to a licensing agreement for its product development platform ( PDP ). According to a press release from the company, it has licensed this to a clinical-stage biotech company for an upfront payment of $3 million.

Why Is Tracon Pharmaceuticals (TCON) Stock Down 22% Today?
Why Is Tracon Pharmaceuticals (TCON) Stock Down 22% Today?
Why Is Tracon Pharmaceuticals (TCON) Stock Down 22% Today?
TCON
InvestorPlace13 November 2023

Tracon Pharmaceuticals (NASDAQ: TCON ) stock is falling on Monday as the company's shares retreat from a massive rally on Friday. That rally saw shares of TCON stock climb 43.9% higher during normal trading hours.

Why Is Tracon Pharmaceuticals (TCON) Stock Up 130% Today?
Why Is Tracon Pharmaceuticals (TCON) Stock Up 130% Today?
Why Is Tracon Pharmaceuticals (TCON) Stock Up 130% Today?
TCON
InvestorPlace10 November 2023

Tracon Pharmaceuticals (NASDAQ: TCON ) stock is rocketing higher on Friday after the biopharmaceutical company announced results for the third quarter of 2023. Tracon Pharmaceuticals starts its report with adjusted earnings per share of 29 cents.

TRACON Pharmaceuticals, Inc. (TCON) Q3 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (TCON) Q3 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (TCON) Q3 2023 Earnings Call Transcript
TCON
Seeking Alpha09 November 2023

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants Dr. Charles Theuer - President and CEO Scott Brown - CFO Conference Call Participants Ed White - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Third Quarter 2023 Earnings Conference Call.

TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
TCON
GlobeNewsWire05 September 2023

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overview:

TRACON Pharmaceuticals, Inc. (TCON) Q2 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (TCON) Q2 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (TCON) Q2 2023 Earnings Call Transcript
TCON
Seeking Alpha14 August 2023

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q2 2023 Earnings Call August 14, 2023 4:30 PM ET Company Participants Charles P. Theuer - President and CEO Scott B.

TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023
TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023
TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023
TCON
GlobeNewsWire02 August 2023

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its second quarter 2023 financial and operating results after the close of U.S. financial markets on Monday, August 14, 2023. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of TRACON Pharmaceuticals?
  • What is the ticker symbol for TRACON Pharmaceuticals?
  • Does TRACON Pharmaceuticals pay dividends?
  • What sector is TRACON Pharmaceuticals in?
  • What industry is TRACON Pharmaceuticals in?
  • What country is TRACON Pharmaceuticals based in?
  • When did TRACON Pharmaceuticals go public?
  • Is TRACON Pharmaceuticals in the S&P 500?
  • Is TRACON Pharmaceuticals in the NASDAQ 100?
  • Is TRACON Pharmaceuticals in the Dow Jones?
  • When was TRACON Pharmaceuticals's last earnings report?
  • When does TRACON Pharmaceuticals report earnings?
  • Should I buy TRACON Pharmaceuticals stock now?

What is the primary business of TRACON Pharmaceuticals?

TCON (TRACON Pharmaceuticals) is a biopharmaceutical company focused on developing targeted therapies for cancer and other diseases. They aim to improve patient outcomes through innovative treatments, leveraging advanced technology and research to address unmet medical needs in oncology.

What is the ticker symbol for TRACON Pharmaceuticals?

The ticker symbol for TRACON Pharmaceuticals is NASDAQ:TCON

Does TRACON Pharmaceuticals pay dividends?

No, TRACON Pharmaceuticals does not pay dividends

What sector is TRACON Pharmaceuticals in?

TRACON Pharmaceuticals is in the Healthcare sector

What industry is TRACON Pharmaceuticals in?

TRACON Pharmaceuticals is in the Biotechnology industry

What country is TRACON Pharmaceuticals based in?

TRACON Pharmaceuticals is headquartered in United States

When did TRACON Pharmaceuticals go public?

TRACON Pharmaceuticals's initial public offering (IPO) was on 30 January 2015

Is TRACON Pharmaceuticals in the S&P 500?

No, TRACON Pharmaceuticals is not included in the S&P 500 index

Is TRACON Pharmaceuticals in the NASDAQ 100?

No, TRACON Pharmaceuticals is not included in the NASDAQ 100 index

Is TRACON Pharmaceuticals in the Dow Jones?

No, TRACON Pharmaceuticals is not included in the Dow Jones index

When was TRACON Pharmaceuticals's last earnings report?

TRACON Pharmaceuticals's most recent earnings report was on 22 November 2024

When does TRACON Pharmaceuticals report earnings?

The date for TRACON Pharmaceuticals's next earnings report has not been announced yet

Should I buy TRACON Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions